TriNetX launches new offering as it continues ‘re-imagining’ clinical research: CEO

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/BrianAJackson)
(Image: Getty/BrianAJackson)
The global health research network today has announced the availability of TriNetX Research, a suite of analytics solutions designed to leverage real-world data during observational and outcomes research.

The self-service platform combines longitudinal clinical and genomic data from the company’s global network​ of more than 100m patients from more than 70 healthcare organizations and 11 countries.

“TriNetX has been re-imagining many facets of clinical research in an effort to expedite the speed at which new therapies are brought to market,”​ said Gadi Lachman, CEO, TriNetX.

“Many vendors in the space offer either the data or the analytics tools,” ​he told us. However, TriNetX’s solution combines clinical data with analytics and presents it via a single web-based platform, Lachman said.

“Given the growing increase in demand from all areas of healthcare, the desire to optimize patient care with precision medicine, and reduce the current costs to bring new therapies to market, it is important to reduce the burden to gain data-driven insights,”​ he added.

David Fusari, CTO, TriNetX, said the company spends a “considerable amount of time” ​focused on ensuring it supports “strong foundational elements of RWE,”​ such as full auditability and transparency.

Moving forward, Fusari said the company will continue to expand the platform’s capabilities to support “hypothesis generation and deeper data exploration”​ to “uncover not yet well understood clinical correlations through advanced machine learning and AI techniques that we have already begun to design.”

As it further develops its global research network – most recently with the addition of Puls Hospital in Bulgaria – Lachman said the company will continue to augment and extend the data available to users.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers